These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657 [No Abstract] [Full Text] [Related]
23. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy. Zhang P; Xu M; Ding J; Chen J; Zhang T; Huo L; Liu Z Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1985-1996. PubMed ID: 34746969 [TBL] [Abstract][Full Text] [Related]
24. Clinical translation of a novel FAPI dimer [ Tan Y; Li J; Zhao T; Zhou M; Liu K; Xiang S; Tang Y; Jakobsson V; Xu P; Chen X; Zhang J Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2761-2773. PubMed ID: 38561515 [TBL] [Abstract][Full Text] [Related]
25. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an Toms J; Kogler J; Maschauer S; Daniel C; Schmidkonz C; Kuwert T; Prante O J Nucl Med; 2020 Dec; 61(12):1806-1813. PubMed ID: 32332144 [TBL] [Abstract][Full Text] [Related]
26. [ Shang Y; Zhang G; Yao X; Lai C; Wang F; Zeng B; Liu E; Yuan H; Cheng Z; Jiang L Mol Imaging Biol; 2024 Aug; 26(4):729-737. PubMed ID: 38987449 [TBL] [Abstract][Full Text] [Related]
27. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Privé BM; Boussihmad MA; Timmermans B; van Gemert WA; Peters SMB; Derks YHW; van Lith SAM; Mehra N; Nagarajah J; Heskamp S; Westdorp H Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1906-1918. PubMed ID: 36813980 [TBL] [Abstract][Full Text] [Related]
28. Li H; Ye S; Li Li ; Zhong J; Yan Q; Zhong Y; Feng P; Hu K Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2705-2715. PubMed ID: 35290473 [TBL] [Abstract][Full Text] [Related]
29. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency. Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470 [TBL] [Abstract][Full Text] [Related]
30. Biodistribution, pharmacokinetics, dosimetry of [ Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Tripathi M; ArunRaj ST; Sarswat S; Bal C Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1915-1931. PubMed ID: 33244617 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and Preclinical Evaluation of a Novel FAPI-04 Dimer for Cancer Theranostics. Zhong X; Guo J; Han X; Wu W; Yang R; Zhang J; Shao G Mol Pharm; 2023 May; 20(5):2402-2414. PubMed ID: 37015025 [TBL] [Abstract][Full Text] [Related]
33. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy. Bendre S; Merkens H; Kuo HT; Ng P; Wong AAWL; Lau WS; Zhang Z; Kurkowska S; Chen CC; Uribe C; Bénard F; Lin KS Eur J Med Chem; 2024 Mar; 268():116238. PubMed ID: 38367492 [TBL] [Abstract][Full Text] [Related]
34. Design and Development of Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911 [TBL] [Abstract][Full Text] [Related]
35. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation. Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165 [TBL] [Abstract][Full Text] [Related]
36. Head-to-Head Comparison of [ Ballal S; Yadav MP; Roesch F; Raju S; Satapathy S; Sheokand P; Moon ES; Martin M; Awarwal S; Tripathi M; Bal C Thyroid; 2023 Aug; 33(8):974-982. PubMed ID: 37171126 [No Abstract] [Full Text] [Related]